ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 683

Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis

María Victoria Martire1, María Paula Girard Bosch1, Santiago Scarafia2, Vanesa Laura Cosentino3, María Janina Tapia4, Eduardo Kerzberg3, Natalia Estrella5, Cristian Troitiño6, Josefina Marin7, Fernando Andres Sommerfleck8, Hernán Maldonado Ficco9, Erika Catay10, Mariana Benegas11 and Enrique R Soriano12, 1Rheumatology, Instituto Médico Platense, La Plata, Argentina, 2Rheumatology, Instituto de Asistencia Reumatológica Integral, Buenos Aires, Argentina, 3Ramos Mejía Hospital, Buenos Aires, Argentina, 4Reumatology, Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina, 5Consultorio Privado, Buenos Aires, Argentina, 6Reumatologia, Hospital Bernardino Rivadavia, CAPITAL FEDERAL, Argentina, 7Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 9section of Rheumatology, Clinica Regional Del Sud, Rio Cuarto, Argentina, 10Consultorios Moreno, Formosa, Argentina, 11Rheumatology Section, Sanatorio Dr. Julio Méndez, Buenos Aires, Argentina, 12Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ,

Session Information

Date: Sunday, October 21, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic Arthritis (PSA) is preceded by the presence of cutaneous psoriasis (PS) in approximately 80% of the cases. We consider relevant to have tools that allow the detection of PSA in that population. The aim of this study was to evaluate the validity and performance of an adapted version of the GEPARD questionnaire in Spanish (GEPARDa) in a group of Argentinean patients with PS.

Methods: Adults >18 years who were able to read and understand Spanish were included. The questionnaire was translated from the original language (German) by two independent translators and retranslation into Spanish was made by another two translators. The performance of the questionnaire was evaluated in its new version (GEPARDa) as a diagnostic test.

Results: 83 patients were included, 55 (66.3%) were women, with a mean age of 50.7 (SD 6.3). Of the patients evaluated, 29 (34.9%) had PSA, 15 (18%) were diagnosed with PSA after referral by dermatology, 18 (21.6%) had PS without joint involvement, 6 patients had PS associated with osteoarthritis (OA) (7.22%) and 15 (18%) were diagnosed with OA. The differences in the means of the GEPARD questionnaire among the different groups were statistically significant between patients with known PSA and patients with PS, PS and OA and OA. There were no differences between patients with PSA and newly diagnosed PSA (Table 1). The area under the curve, considering as the gold standard the CASPAR criteria, was 0.9554 DS 0.01 (95% CI 0.91-0.99). A score of 6 was determined to be the better cut-off point for distinguishing PSA from non- PSA. With this value, sensitivity was 88.64%, specificity of 89.74%, LR + of 8.6 and LR – 0.12. Five false negatives were found. 4 patients had a false positive diagnosis. Table 2 shows the relationship of the variables studied and the positivity of the GEPARDa questionnaire. After the multivariate analysis, the variable that was associated with the positivity of the questionnaire was the DAS28 (OR 2.93, 95% CI 0.13-0.91, p: 0.03).

Conclusion: The GEPARDa version is an excellent tool for the detection of PSA in argentine patients with PS.

TABLE 1. Differences of GEPARDa in the evaluated groups.

Variables

PSA

PSA new diagnosis

PS

PS + OA

OA

Median (IQR)

9 (7-10.5)

8 (5-12)

1 (0.2.75)

4 (3-5)

4 (3-5)

p-value (vs APS)

 

1

<0.001

0.60

<0.001

mean (SD)

8.9 (2.3)

8.6 (3.11)

1.78 (2.4)

4 (1.09)

4.13 (1.4)

p-value (vs PSA)

 

0.99

<0.001

<0.001

<0.001

TABLE 2. Associations between GEPARDa >= 6 and studied variables.

Variables

GEPARDa >= 6

GEPARDa <6

p -value

Female n

27

28

0.48 (-0.29-0.13)

Age m (DS)

49.9 (15.3)

51.5 (15.2)

0.62 (45-54)

Years of education mean (SD)

13.17(4.5)

12.93 (4.1)

0.82 (12.14.15)

Intergluteo Commitment n

20

9

0.21 (-0.2-0.41)

Scalp Commitment n

25

11

0.12 (0.18-0.45)

Ungueal commitment n

19

6

0.6 (0.08-0.47)

Smoking n

14

8

0.62 (0.47-3.6)

Pack/years mean (SD)

3.05(5.84)

3.32 (6.49)

0.85 (1.7-4.6)

Body max index mean (SD)

26.72

25.4

0.47 (24.3-27.9)

 

Disclosure: M. V. Martire, None; M. P. Girard Bosch, None; S. Scarafia, None; V. L. Cosentino, None; M. J. Tapia, None; E. Kerzberg, None; N. Estrella, None; C. Troitiño, None; J. Marin, None; F. A. Sommerfleck, None; H. Maldonado Ficco, None; E. Catay, None; M. Benegas, None; E. R. Soriano, AbbVie, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer Inc, Roche, UCB, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, 5,AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sandoz, UCB, 8.

To cite this abstract in AMA style:

Martire MV, Girard Bosch MP, Scarafia S, Cosentino VL, Tapia MJ, Kerzberg E, Estrella N, Troitiño C, Marin J, Sommerfleck FA, Maldonado Ficco H, Catay E, Benegas M, Soriano ER. Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/spanish-validation-of-the-gepard-questionnaire-for-the-detection-of-psoriatic-arthritis-in-argentinean-patients-with-psoriasis/. Accessed .

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spanish-validation-of-the-gepard-questionnaire-for-the-detection-of-psoriatic-arthritis-in-argentinean-patients-with-psoriasis/